Pharmacokinetics, Efficacy and Safety of a Plasma-Derived VWF/FVIII Concentrate (Formulation V) in Pediatric Patients with von Willebrand Disease (SWIFTLY-VWD Study)

References

• Barr RD, Sek J, Horsman J, et al. Health status and health-related quality of life associated with von Willebrand disease. Am J Hematol. 2003;73(2):108–114. doi:10.1002/ajh.1032712749012
   PubMed Web of Science ®Google Scholar
• Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171–232. doi:10.1111/j.1365-2516.2007.01643.x18315614
   PubMed Web of Science ®Google Scholar
• Flood VH, Montgomery RR. von Willebrand disease: biologic diagnosis In: Lee CA, Berntorp EE, Hoots WK, editors. Textbook of Hemophilia. Oxford, UK: Wiley-Blackwell; 2010:294–301.
   Google Scholar
• Heijdra JM, Cnossen MH, Leebeek FWG. Current and emerging options for the management of inherited von Willebrand disease. Drugs. 2017;77(14):1531–1547. doi:10.1007/s40265-017-0793-228791655
   PubMed Web of Science ®Google Scholar
• Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103–2114. doi:10.1111/j.1538-7836.2006.02146.x16889557
   PubMed Web of Science ®Google Scholar
• Mannucci PM. How I treat patients with von Willebrand disease. Blood. 2001;97(7):1915–1919. doi:10.1182/blood.V97.7.191511264151
   PubMed Web of Science ®Google Scholar
• Castaman G, Linari S. Human von Willebrand factor/factor VIII concentrates in the management of pediatric patients with von Willebrand disease/hemophilia A. Ther Clin Risk Manag. 2016;12:1029–1037. doi:10.2147/TCRM.S8754327445481
   PubMed Web of Science ®Google Scholar
• Federici AB, Mannucci PM. Diagnosis and management of von Willebrand disease. Haemophilia. 1999;5(Suppl 2):28–37. doi:10.1046/j.1365-2516.1999.0050s2028.x
   Web of Science ®Google Scholar
• Laffan MA, Lester W, O’Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia centre doctors organization guideline approved by the British committee for standards in haematology. Br J Haematol. 2014;167(4):453–465. doi:10.1111/bjh.1306425113304
   PubMed Web of Science ®Google Scholar
• CSL Behring. VONCENTO® Summary of Product Characteristics. 2018 Available from: https://www.medicines.org.uk/emc/product/5341/. Accessed 622, 2018.
   Google Scholar
• Lissitchkov TJ, Buevich E, Kuliczkowski K, et al. Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study). Blood Coagul Fibrinolysis. 2017;28(2):152–162. doi:10.1097/MBC.000000000000056827203734
   PubMed Web of Science ®Google Scholar
• Harper P, Favaloro EJ, Curtin J, Barnes C, Dunkley S. Human plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety data. Drugs Context. 2016;5:212292. doi:10.7573/dic.21229227114741
   PubMedGoogle Scholar
• Skotnicki A, Lissitchkov TJ, Mamonov V, et al. Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO(R)) in subjects with haemophilia A (SWIFT-HA study). Thromb Res. 2016;137:119–125. doi:10.1016/j.thromres.2015.10.01426614676
   PubMed Web of Science ®Google Scholar
• EMA guideline on the clinical investigation of human plasma derived von Willebrand factor products (CPMP/BPWG/220/02). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500067126.pdf. Accessed 417, 2020.
   Google Scholar
• Federici AB, Castaman G, Franchini M, et al. Clinical use of haemate P in inherited von Willebrand’s disease: a cohort study on 100 Italian patients. Haematologica. 2007;92(7):944–951. doi:10.3324/haematol.1112417606445
   PubMed Web of Science ®Google Scholar
• Windyga J, von Depka-prondzinski M, European Wilate Study G. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate(R)) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost. 2011;105(6):1072–1079. doi:10.1160/TH10-10-063121437358
   PubMed Web of Science ®Google Scholar
• Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost. 2007;5(6):1115–1124. doi:10.1111/j.1538-7836.2007.02562.x17403090
   PubMed Web of Science ®Google Scholar
• Shire. VONVENDI® Prescribing Information. 2018 Available from: https://www.shirecontent.com/PI/PDFs/VONVENDI_USA_ENG.pdf. Accessed 622, 2018.
   Google Scholar
• Coppola A, Franchini M, Makris M, Santagostino E, Di Minno G, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia. 2012;18(3):e173–e187. doi:10.1111/j.1365-2516.2012.02758.x22335611
   PubMed Web of Science ®Google Scholar
• Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345(8943):152–155. doi:10.1016/S0140-6736(95)90166-37823669
   PubMed Web of Science ®Google Scholar
• Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost. 2002;88(3):387–388. doi:10.1055/s-0037-161322712353065
   PubMed Web of Science ®Google Scholar
• Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost. 2002;88(3):378–379. doi:10.1055/s-0037-161322512353063
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Chediak J, Hanna W, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002;99(2):450–456. doi:10.1182/blood.V99.2.45011781224
   PubMed Web of Science ®Google Scholar
• CSL Behring. HAEMATE P® summary of product characteristics. 2018 Available from: https://www.medicines.org.uk/emc/medicine/19412. Accessed 622, 2018.
   Google Scholar
• LFB Biopharmaceuticals. WILLFACT® summary of product characteristics. 2016 Available from: https://www.medicines.org.uk/emc/medicine/29947. Accessed 622, 2018.
   Google Scholar
• Octapharma. WILATE® summary of product characteristics. 2014 Available from: https://www.medicines.org.uk/emc/medicine/27202. Accessed 622, 2018.
   Google Scholar
• Favaloro EJ, Lloyd J, Rowell J, et al. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [BiostateandAHF(HighPurity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. Thromb Haemost. 2007;97(6):922–930. doi:10.1160/TH06-09-049517549293
   PubMed Web of Science ®Google Scholar
• Dunkley S, Baker RI, Pidcock M, et al. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand’s disease: a prospective multi-centre study. Haemophilia. 2010;16(4):615–624. doi:10.1111/j.1365-2516.2010.02206.x20331755
   PubMed Web of Science ®Google Scholar
• Shortt J, Dunkley S, Rickard K, Baker R, Street A. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures. Haemophilia. 2007;13(2):144–148. doi:10.1111/j.1365-2516.2006.01430.x17286766
   PubMed Web of Science ®Google Scholar
• Howman R, Barnes C, Curtin J, et al. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE(R), in children with von Willebrand disorder: a multi-centre retrospective review. Haemophilia. 2011;17(3):463–469. doi:10.1111/j.1365-2516.2010.02445.x21118340
   PubMed Web of Science ®Google Scholar
• Berntorp E, Archey W, Auerswald G, et al. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/Humate -P: history and clinical performance. Eur J Haematol Suppl. 2008;70:3–35. doi:10.1111/j.1600-0609.2008.01049.x
   Google Scholar
• Berntorp E, Windyga J, European Wilate Study Group. Treatment and prevention of acute bleedings in von Willebrand disease–efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate. Haemophilia. 2009;15(1):122–130. doi:10.1111/j.1365-2516.2008.01901.x19149848
   PubMed Web of Science ®Google Scholar
• Federici AB, James P. Current management of patients with severe von Willebrand disease type 3: a 2012 update. Acta Haematol. 2012;128(2):88–99. doi:10.1159/00033820822722677
   PubMed Web of Science ®Google Scholar